ALFA Finder| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 25.73% YoY consolidated revenue growth. |
|---|---|
| Margins | EBITDA margins rose to 26% from 17% YoY. |
| Order book | Management mentions a healthy order pipeline. |
| Demand visibility | Improving demand across key end-user industries. |
| Management confidence | High; citing healthy order pipeline and disciplined execution. |
Growth
Consolidated Revenue grew 25.7% YoY; PAT surged 110% YoY to ₹78 Cr. EBITDA margins expanded to 26%.
Outlook
Guided 10-15% volume growth for FY27 and 20-30% medium-term. EBITDA margin target 22-23% for FY27. ₹1000 Cr+ capex cycle nearing completion.
Risks
Global macroeconomic headwinds and West Asia crisis mentioned as ongoing external challenges.
Last quarter's promises, checked
Delivered
- Guided 10-15% volume growth → delivered 25.7% revenue growth (= BEAT)
- Guided EBITDA margin 22-23% → delivered 26% (= BEAT)
- Commission DME plant in Q1FY27 → delivered commissioning of 100,000 TPA plant (= BEAT)
Partly delivered
- Guided standalone debt-free → delivered standalone debt-free but consolidated debt remains (= PARTIAL)
Investor Presentation filed with BSE, NSE: BALAMINES. Summary written with AI assistance from the document.
Balaji Amines Ltd: key numbers
- Share price
- ₹1,838.00
- Market cap
- ₹5,955 Cr
- Revenue (annual)
- ₹1,425 Cr
- Net profit (annual)
- ₹167.2 Cr
- P/E (TTM)
- 25.2×Sector 35.5×
- Promoter holding
- 54.56%+0.00% QoQ
- FII holding
- 3.25%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaji Amines Ltd
All →Balaji Amines Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue rose 36% YoY to ₹472 Cr and PAT rose 82%, but volumes fell 6% YoY and EBITDA dropped QoQ from ₹121 Cr to ₹106 Cr.
Balaji Amines Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹472 Cr (+36% YoY), EBITDA ₹106 Cr (22% margin), PAT ₹67 Cr (+82%). H1 consolidated PAT ₹146 Cr. Standalone debt-free; DME, ACN commercialised; NMM and BSCL expansions ongoing.
Balaji Amines Legal & Regulatory
Balaji Amines received summons from Ahmedabad City Civil Court over alleged Drugs and Cosmetics Act violations. The company states no material financial or operational impact.
Balaji Amines Results Update
Balaji Amines reported Q2 FY27 consolidated revenue of ₹472 Cr and net profit of ₹67 Cr. Its expanded ACN facility reached 1,440 TPM capacity with commercial production commenced.
- Acetonitrile (ACN) manufacturing capacity
- 1440 TPM
Balaji Amines Q2 FY27 Results: Net Profit ₹67.5 Cr, Up 81.9% YoY
Balaji Amines Ltd reported revenue from operations of ₹467.6 Cr (+37.3% YoY) and net profit of ₹67.5 Cr (+81.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹67.5 Cr · +81.9% YoY
Balaji Amines Board Meeting Date
Balaji Amines scheduled a board meeting on 2 November 2026 for September 2026 quarter and half-year results. Trading window reopens 48 hours after results.